Mastek Limited Q1 FY27 Earnings Call Summary

Event Participants

Executives

2 Deepak Kedia, Umang Nahata

Analysts

4 Amit Chandra (HDFC Securities), Devang Bhatt (Spark PWM), Pulkit Chawla (360 One Capital), Sushovon (Anand Rathi)

Financials & KPIs

Geographic & Segment Commentary

• U.K.: Grew 3% QoQ in constant currency with healthy EBIT of ~20%. Banking/financial services ramp-up (led by FCA) is driving growth; healthcare is transitioning from closed legacy NHS England projects to new data modernization/data platform work; public sector remains stable with new local government wins. Management is closely monitoring the new government's policy and budget priorities.
• North America: Grew ~2% QoQ in constant currency and 6% in INR; backlog up 29.8% QoQ and 23.5% YoY on a third consecutive quarter of strong order intake, led by a $25 million, 5-year Salesforce Agentforce AI transformation deal. Healthcare & Life Sciences is the key vertical; management expects the region to become a growth engine by H2 FY27.
• Middle East (AMEA): Severe headwinds from the West Asia crisis are creating unpredictability; bench cost and delayed collections hit Q1 EBITDA. Some new orders (including a large healthcare deal) were signed late in the quarter, but ramp-up predictability remains uncertain—flat at best unless geopolitical stability returns.
• Healthcare (vertical): Strong demand continues, especially in data modernization; Q1 saw a timing gap as old projects ramped down and new ones started. U.K. healthcare to recover from Q2 and reach prior levels by H2; U.S. Healthcare & Life Sciences ramp expected in H2; Middle East healthcare has a strong order book but uncertain execution.
• Public Sector (vertical): Grew 7.9% sequentially on stable existing customer performance and new local government acquisitions; high demand for cost savings and efficiency. Political leadership change is being watched closely for budget implications.
• Data, Automation & AI: Grew 9.8% sequentially; 40+ AI-led deal wins closed in Q1, reinforcing the AI transformation focus.

Company-Specific & Strategic Commentary

• AI Transformation Positioning: Steering Mastek toward becoming an AI transformation company in select verticals (healthcare, public sector), leveraging enterprise application transformation, a strong data practice, and engineering. 40+ AI-led deals closed in the quarter; an AI maturity model (Level 0–5) is being applied across all existing customers over the next 90–180 days.
• "Customer Zero" Internal Transformation: Executing a significant AI-led business transformation internally—core systems (CRM, recruitment, payables) have been replaced with AI-native "Service-as-a-Software" solutions targeting outcomes such as recruitment cycle time, win predictability, and G&A cost efficiency; these also serve as client case studies.
• Leadership & Talent: Amit Gajwani (ex-LTM) appointed COO to drive delivery governance, talent transformation, and an outcome-focused culture; resources are shifting from engineering to forward-deployed engineering (FDEs) and forward-deployed domain consultants (FDDCs).
• Deal Pipeline & Pricing: Large deal pipeline has improved and is well-qualified across geographies; TCV is growing faster than ACV (e.g., 5-year, $25 million North America deal). Renewals face aggressive pricing—typically ~15%, up to 20–25% in isolated cases—but not the irrational 50%+ discounts reported by peers.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Deal Ramp-ups and Top-5 Client Decline

• Question: When will FCA, HADES and the U.S. deal ramp, and why did top-5 clients decline 4% QoQ and 12% YoY? (Sushovon, Anand Rathi)
• Answer: FCA is already ramping—driving U.K. banking/financial services growth—with more ramp-up in Q2; HADES is a renewal of an existing customer with steady revenue; the U.S. deal ramps in H2 FY27. The top-5 decline is a timing gap at NHS England healthcare—old project closed, new data modernization/data platform project ramping from Q2. (Umang Nahata)

Subcon and ESOP Costs

• Question: Is subcon cost increasing as a % of revenue, and what will be the ESOP impact going forward? (Sushovon)
• Answer: Subcon is 18.5% of revenue, in line with Q4. ESOP grants begin in Q2 at an estimated impact of $400,000–500,000 per quarter. (Deepak Kedia)

TCV Trends, Discounting and Healthcare Recovery

• Question: How have TCV trends been, are discounts becoming irrational (50%+ at peers), and will healthcare return to sequential growth from Q2? (Pulkit Chawla, 360 One Capital)
• Answer: Total order book/TCV is healthy—the $25 million North America deal is a 5-year contract, so TCV growth exceeds backlog growth. Discounts are aggressive but not at 50%; generally ~15%, topping at 20–25% in 1–2 cases; fixed-bid/outcome-based contracts should boost execution margins. U.K. healthcare ramps from Q2 and reaches prior levels by H2; U.S. healthcare/life sciences ramp is H2 (Q2 not firm); Middle East healthcare has a strong order book but uncertain ramp. (Umang Nahata)

Order Book Quality, Middle East Ramp and Geographic Margins

• Question: Excluding the $25 million U.S. deal, backlog looks flat sequentially—how is the funnel, when will the large Middle East deal ramp, and will U.S./Middle East margins stay suppressed? (Amit Chandra, HDFC Securities)
• Answer: The pipeline is consistently improving with more large, well-qualified opportunities across geographies—a change from earlier. The Middle East healthcare deal has started with a planned immediate ramp-up, but the environment is volatile; client signals indicate intent to proceed. Middle East margin pressure (bench, collections) should reverse during the year; North America needs to reach a $28–30 million quarterly run rate to deliver mid-teens margins. (Umang Nahata)

AI Deal Sources and Go-to-Market

• Question: Are AI deal wins coming from existing accounts or net new engagements? (Amit Chandra)
• Answer: All three motions are active: (1) existing clients via an AI maturity model (Level 0–5) covering the full base in 90–180 days; (2) net new through Oracle, Salesforce, Snowflake and Databricks relationships embedding AI components; (3) a "champion challenger" push in new accounts offering pricing competitiveness versus large incumbents. (Umang Nahata)

Demand Environment and EBITDA Margin Bridge

• Question: What changed versus the subdued Q4 commentary, and what drove the Q4-to-Q1 EBITDA change? (Sushovon)
• Answer: Business is trending in the same direction as Q4—executing the backlog built over 3–4 quarters; U.K. healthcare demand remains phenomenal, public sector is stable, North America order book has improved for 3 quarters, and AI-led opportunities are picking up. EBITDA was hit by Middle East delayed collections, doubtful/unbilled provisions, mix change, and U.K. regulatory costs, offset by cost efficiency and currency tailwind. (Umang Nahata, Deepak Kedia)

Steady-State Margin Outlook

• Question: With ESOP adding ~25 bps impact, what is the steady-state EBITDA/EBIT margin? (Sushovon)
• Answer: Q2 will see ESOP cost plus annual increments, so margins will be impacted; no full-year guidance, but internal cost efficiencies will mitigate a significant portion of the impact. ESOP is a strategic investment for long-term team stability and the transformation journey. (Deepak Kedia, Umang Nahata)

Growth Sustainability and Headwinds

• Question: Can QoQ revenue momentum continue from Q4–Q1, and are there headwinds beyond Middle East? (Devang Bhatt, Spark PWM)
• Answer: U.K. delivery is comfortable; North America needs 1–2 more good quarters to become a growth engine by H2. Key headwinds are Middle East uncertainty and AI-led competition—incumbents challenging Mastek's existing turf. Directionally, FY27 should be better than FY26, but no formal guidance is given; protecting the installed base is critical. (Umang Nahata)

Key Takeaway

Mastek delivered Q1 FY27 revenue of $104.8 million (₹985 crore, +5% QoQ INR, +1.8% QoQ CC) with operating EBITDA margin of 15.4%, weighed down by Middle East bench costs and delayed collections. The 12-month order backlog reached $310 million (+3.2% QoQ, +25% YoY INR), supported by U.K. stability, a 5-year, $25 million Salesforce Agentforce deal in North America, and 40+ AI-led wins. Management is positioning Mastek as an AI transformation company—driving an internal "Customer Zero" program (AI-native CRM, recruitment, payables), onboarding COO Amit Gajwani, and shifting talent toward forward-deployed engineering and domain consulting. Healthcare's NHS transition caused a one-time top-5 revenue dip, with U.K. recovery expected from Q2 and North America becoming a growth engine by H2 FY27. Management directionally expects FY27 revenue to exceed FY26, though ESOP costs (~$400,000–500,000/quarter), Q2 increments, Middle East volatility, and aggressive AI-driven pricing remain key watch points.